Gjertsen Lab Publications 2012-23

List of publications 2012 – 2023

Publication Statistics: Number of publications: 270 (PubMed.gov; 01DEC2023), Web of Science Clarivate Analytics (07MAY2023): 385 published items, times cited: 9,330, h-index 49. Google Scholar 13784 citations, h-index 63. First authorships: 15 (incl. two shared first author). Second author: 21. Senior author: 63.

ORCID ID: 0000-0001-9358-9704

* highlights papers of particular importance for the laboratory and group:

Research papers published in peer reviewed journals:

  1. *Tislevoll B, Hellesøy M, Fagerholt O, Gullaksen S-E, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele D, Skavland J, Panagiotis B, Hovland R, Andresen V, Seternes O-M, Tvedt TH, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT. Early response evaluation by single cell signaling profiling in acute myeloid leukemia. Nature Commun, 2023; DOI 10.1038/s41467-022-35624-4. IF 17.694 *Impact: Single cell analysis of signaling 24 h after start of chemotherapy correlate with superior significance with 5 year survival. This paper prepares for validation and development of signaling-based functional diagnostics.
  2. Tettero JM, Buisman Y, Ngai LL, Bachas C, Gjertsen BT, Kelder A, van de Loosdrecht AA, Manz MG, Pabst T, Scholten W, Ossenkoppele GJ, Cloos J, de Leeuw DC. Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML. 2023 Nov 21;7(12):e981. doi: 10.1097/HS9.0000000000000981. PMID: 38026789; PMCID: PMC10664848.
  3. Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G. WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy. 2023 Sep;37(9):1842-1849. doi: 10.1038/s41375-023-01980-3. PMID: 37507426.
  4. Erikstein BS, Ahmed AB, Forthun RB, Leh F, Gjertsen BT, Reikvam H. Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome. J Hematol. 2023 Apr;12(2):92-99. doi: 10.14740/jh1107. PMID: 37187497; PMCID: PMC10181328.
  5. Geelen IGP, Gullaksen SE, Ilander MM, Olssen-Strömberg U, Mustjoki S, Richter J, Blijlevens NMA, Smit WM, Gjertsen BT, Gedde-Dahl T, Markevärn B, Koppes MMA, Westerweel PE, Hjorth-Hansen H, Janssen JJWM. Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects. Ann Hematol. 2023 Jun;102(6):1395-1408. doi: 10.1007/s00277-023-05199-1. PMID: 37119314.
  6. Tettero JM, Ngai LL, Bachas C, Breems DA, Fischer T, Gjertsen BT, Gradowska P, Griskevicius L, Janssen JJWM, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Valk PJM, Löwenberg B, Ossenkoppele GJ, Cloos J. Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. 2023 Apr 6. doi: 10.3324/haematol.2022.282639. PMID: 37021540.
  7. Thomsen LCV, Honoré A, Reisæter LAR, Almås B, Børretzen A, Helle SI, Førde K, Kristoffersen EK, Kaada SH, Melve GK, Haslerud TM, Biermann M, Bigalke I, Kvalheim G, Azeem W, Olsen JR, Gabriel B, Knappskog S, Halvorsen OJ, Akslen LA, Bahn D, Pantel K, Riethdorf S, Ragde H, Gjertsen BT, Øyan AM, Kalland KH, Beisland C. A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2023 Jul;72(7):2357-2373. doi: 10.1007/s00262-023-03421-7. PMID: 36939854; PMCID: PMC10264291.
  8. Falini B, Martelli MP, Brunetti L, Gjertsen BT, Andresen V. The NPM1 mutant defines AML irrespective of blast count. Am J Hematol. 2023 Jul;98(7):E187-E189. doi: 10.1002/ajh.26946. PMID: 37119006.
  9. Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, Kelder A, Oudshoorn-van Marsbergen L, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, Cloos J. Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial. 2023 May 25;141(21):2657-2661. doi: 10.1182/blood.2022019160. PMID: 36898087.
  10. *Othman J, Meggendorfer M, Tiacci E, Thiede C, Schlenk R, Dillon R, Stasik S, Venanzi A, Bertoli S, Delabesse E, Dumas PY, Pigneux A, Bidet A, Gilkes AF, Thomas I, Voso MT, Rambaldi A, Brunetti L, Perriello VM, Andresen V, Gjertsen BT, Martelli MP, Récher C, Röllig C, Bornhäuser M, Serve H, Müller-Tidow C, Baldus CD, Haferlach T, Russell N, Falini B. Overlapping features of therapy-related and de novo NPM1-mutated AML. 2023 Apr 13;141(15):1846-1857. doi: 10.1182/blood.2022018108. PMID: 36508705.
  11. *Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J. Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. P
  12. Huuhtanen J, Ilander M, Yadav B, Dufva OM, Lähteenmäki H, Kasanen T, Klievink J, Olsson-Strömberg U, Stentoft J, Richter J, Koskenvesa P, Höglund M, Söderlund S, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Stenke L, Myhr-Eriksson K, Markevärn B, Lübking A, Dimitrijevic A, Udby L, Bjerrum OW, Hjorth-Hansen H, Mustjoki S. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia. J Clin Invest. 2022 Sep 1;132(17):e152585. doi: 10.1172/JCI152585.
  13. *Pianigiani G, Rocchio F, Peruzzi S, Andresen V, Bigerna B, Sorcini D, Capurro M, Gjertsen BT, Sportoletti P, Di Ianni M, Martelli MP, Brunetti L, Falini B. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein. 2022 Jul;36(7):1931-1934. doi: 10.1038/s41375-022-01593-2.
  14. Rana N, Suliman S, Mohamed-Ahmed S, Gavasso S, Gjertsen BT, Mustafa K. Systemic and local innate immune responses to surgical co-transplantation of mesenchymal stromal cells and biphasic calcium phosphate for bone regeneration. Acta Biomater. 2022 Mar 15;141:440-453. doi: 10.1016/j.actbio.2021.12.027.
  15. Bakunina K, Putter H, Versluis J, Koster EAS, van der Holt B, Manz MG, Breems DA, Gjertsen BT, Cloos J, Valk PJM, Passweg J, Pabst T, Ossenkoppele GJ, Löwenberg B, Cornelissen JJ, de Wreede LC. The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed. Cancer Med. 2022 Feb;11(3):630-640. doi: 10.1002/cam4.4392.
  16. Johansen S, Laegreid IJ, Ernstsen SL, Azrakhsh NA, Kittang AO, Lindås R, Gjertsen BT, Vetti N, Mørtberg TV, Sørvoll IH, Holme PA, Ahlen MT, Reikvam H. Thrombosis and thrombocytopenia after HPV vaccination. J Thromb Haemost. 2022 Mar;20(3):700-704. doi: 10.1111/jth.15604.
  17. Gundersen ET, Førde JL, Tislevoll BS, Leitch C, Barratt G, Gjertsen BT, Herfindal L. Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. Int J Pharm. 2022 Jan 25;612:121296. doi: 10.1016/j.ijpharm.2021.121296.
  18. *Malani D, Kumar A, Brück O, Kontro M, Yadav B, Hellesøy M, Kuusanmäki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Västrik I, Kivinen K, Saarela J, Räty R, Lehto M, Wolf M, Gjertsen BT, Mustjoki S, Aittokallio T, Wennerberg K, Heckman CA, Kallioniemi O, Porkka K. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2022 Feb;12(2):388-401. doi: 10.1158/2159-8290.CD-21-0410. Epub 2021 Nov 17. PMID: 34789538. IF 39.4.*Impact: Genomics is combined with functional testing of drug sensitivity and resistantce to more that 500 approved small molecule medicines result in 60% therapy response in relapsed / refractory AML. This indicate that responders can be identified with functional testing of cancer cells.
  19. *Hellesøy M, Engen C, Grob T, Löwenberg B, Valk PJM, Gjertsen Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis. Mol Oncol. 2021 Jun 8. doi: 10.1002/1878-0261.13035.
  20. Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T. Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur J Haematol. 2021 May 30. doi: 10.1111/ejh.13672.
  21. *Haaland I, Hjelle SM, Reikvam H, Sulen A, Ryningen A, McCormack E, Bruserud Ø, Gjertsen BT. p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells. 2021 Apr 7;10(4):833. doi: 10.3390/cells10040833.
  22. *Engen C, Hellesøy M, Grob T, Al Hinai A, Brendehaug A, Wergeland L, Bedringaas SL, Hovland R, Valk PJM, Gjertsen FLT3-ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation. Mol Oncol. 2021 Apr 5. doi: 10.1002/1878-0261.12961
  23. Anandan S, Thomsen LCV, Gullaksen SE, Abdelaal T, Kleinmanns K, Skavland J, Bredholt G, Gjertsen BT, McCormack E, Bjørge L. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers (Basel). 2021 Feb 11;13(4):755.
  24. Hemsing AL, Gjertsen BT, Spetalen S, Helgeland L, Reikvam H. Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/ myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. SAGE Open Med Case Rep. 2021 Jan 22;9:2050313X20988413.
  25. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Robak T, le Coutre PD, Gjertsen BT, Troussard X, Roboz GJ, Karlin L, Gladstone DE, Kuptsova-Clarkson N, Liu S, Patel P, Rotolo F, Mitry E, Pastan I, Giles F; Study 1053 investigators. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14(1):35.
  26. *Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M, Silzle T, van Lammeren-Venema D, Moors I, Breems DA, Hoogendoorn M, Legdeur MJC, Fischer T, Kuball J, Cornelissen J, Porkka K, Juliusson G, Meyer P, Höglund M, Gjertsen BT, Janssen JJWM, Huls G, Passweg J, Cloos J, Valk PJM, van Elssen CHMJ, Manz MG, Floisand Y, Ossenkoppele GJ. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. Blood Adv. 2021 Feb 23;5(4):1110-1121.
  27. Mosleth EF, Vedeler CA, Liland KH, McLeod A, Bringeland GH, Kroondijk L, Berven FS, Lysenko A, Rawlings CJ, Eid KE, Opsahl JA, Gjertsen BT, Myhr KM, Gavasso S. Cerebrospinal fluid proteome shows disrupted neuronal development in multiple sclerosis. Sci Rep. 2021 Feb 18;11(1):4087.
  28. Janssen J, Löwenberg B, Manz M, Bargetzi M, Biemond B, Borne PVD, Breems D, Brouwer R, Chalandon Y, Deeren D, Efthymiou A, Gjertsen BT, Graux C, Gregor M, Heim D, Hess U, Hoogendoorn M, Jaspers A, Jie A, Jongen-Lavrencic M, Klein S, Klift MV, Kuball J, Lammeren-Venema DV, Legdeur MC, Loosdrecht AV, Maertens J, Kooy MVM, Moors I, Nijziel M, Obbergh FV, Oosterveld M, Pabst T, Poel MV, Sinnige H, Spertini O, Terpstra W, Tick L, Velden WV, Vekemans MC, Vellenga E, Weerdt O, Westerweel P, Stüssi G, Norden YV, Ossenkoppele G. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel). 2021 Feb 7;13(4):672.
  29. Bredrup C, Cristea I, Safieh LA, Di Maria E, Gjertsen BT, Tveit KS, Thu F, Bull N, Edward DP, Hennekam RCM, Høvding G, Haugen OH, Houge G, Rødahl E, Bruland O. Temperature-dependent autoactivation associated with clinical variability of PDGFRB Asn666 substitutions. Hum Mol Genet. 2021 Jan 15:ddab014. doi: 10.1093/hmg/ddab014.
  30. *Fagerholt OHE, Hellesøy M, Gullaksen SE, Gjertsen BT. Single Cell Detection of the p53 Protein by Mass Cytometry. Cancers (Basel). 2020 Dec 9;12(12):3699. doi: 10.3390/cancers12123699.
  31. Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnova M, Piechaczyk L, Ayuda-Durán P, Singh SK, Gedde-Dahl T, Floisand Y, Skavland J, Wesche J, Gjertsen BT, Enserink JM. A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. J Biol Chem. 2020 Dec 10:jbc.RA120.015285. doi: 10.1074/jbc.RA120.015285.
  32. *Onyango TB, Hjelle SM, Haaland I, Vintermyr OK, Johannessen AC, Gjertsen BT. A Comparison of p53 Isoform Profiles and Apoptosis Induced by Camptothecin or a Herbal Khat Extract (Catha Edulis (Vahl) Forssk. ex Endl.) in Leukemic Cell Lines: Exploring Cellular Responses in Therapy Development. Cancers (Basel). 2020 Dec 1;12(12):3596.
  33. Haugse R, Langer A, Murvold ET, Costea DE, Gjertsen BT, Gilja OH, Kotopoulis S, Ruiz de Garibay G, McCormack E. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Pharmaceutics. 2020 Nov 6;12(11):1058.
  34. Wang X, Deng L, Gjertsen BT. A microfluidic device for differential capture of heterogeneous rare tumor cells with epithelial and mesenchymal phenotypes. Anal Chim Acta. 2020;1129:1-11.
  35. *Tambe M, Karjalainen E, Vähä-Koskela M, Bulanova D, Gjertsen BT, Kontro M, Porkka K, Heckman CA, Wennerberg K. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia, 2020; 10.1038/s41375-020-0972-0.
  36. *Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell-Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. PMID: 32572189; PMCID: PMC7387243.
  37. Alme E, Törnroos KW, Gjertsen BT, Bjørsvik HR. Synthesis of N-Aryl- and N-alkyl-Substituted Imidazolium Silver Complexes: Cytotoxic Screening by Using Human Cell Lines Modelling Acute Myeloid Leukaemia. 2020; 10.1002/cmdc.202000138.
  38. ***Omsland M, Vibeke Andresen V, Gullaksen SE, Ayuda-Durán P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Interferon alpha and tyrosine kinase inhibitors increase tunneling nanotubes (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020 34(3):3773-3791. Citations 10. IF 5.191. Citations 10. IF 5.191. *Impact: The first report on upregulation of TNT by kinase inhibitors indicating that the anti-leukemic interferon-alpha share the same mechanism of action.
  39. Mercatelli D, Bortolotti M, Andresen V, Sulen A, Polito L, Gjertsen BT, Bolognesi A. Early response to the plant toxin stenodactylin in acute myeloid leukemia cells involves inflammatory and apoptotic signaling. Frontiers Pharm. 2020 May 8;11:630.
  40. Bjånes T, Kotopoulis S, Murvold ET, Kamčeva T, Gjertsen BT, Gilja OH, Schjøtt J, Riedel B, McCormack E. Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. 2020;12(2). pii: E141.
  41. Bjørsvik HR, Gjertsen BT, Elumalai V. Hit to Leads with Cytotoxic Effect in Leukemic Cells: Total Synthesis Intermediates as a Molecule Treasure Chest. 2020;15(10):862-870. doi:10.1002/cmdc.202000066
  42. Kleinmanns K, Bischof K, Anandan S, Popa M,Akslen LA Fosse V, Karlsen I, Gjertsen BT, Bjørge L, McCormack E. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. 2020;56:102782.
  43. *Ossenkoppele G, Breems D, Stuessi S, van Norden Y, Bargetzi M, Biemond B, von dem Borne P, Chalandon Y, Cloos J, Deeren D, Fehr M, Gjertsen B, Graux C, Huls G, Janssen J, Jaspers A, Jongen-Lavrencic M, de Jongh E, Klein S, van der Klift M, van Marwijk Kooy M, Maertens J, Michaux L, van der Poel M, van Rhenen A, Tick L, Valk P, Vekemans M-C, van der Velden W, de Weerd Ot, Pabst T, Markus Manz M, Löwenberg B. Lenalidomide added to standard intensive treatment for elderly patients with AML and high risk MDS. 2020;34(7):1751-1759.
  44. *Kuusanmäki H, Leppä A-M, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman C. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemi. Haematologica. 2020;105(3):708-711.
  45. *Gullaksen SE, Bader L, Hellesøy M, Sulen A, Fagerholt OHE, Engen CB, Skavland J, Gjertsen BT, Gavasso S. Titrating Complex Mass Cytometry Panels. Cytometry A. 2019 Apr 9. doi: 10.1002/cyto.a.23751.
  46. Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O. ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab. Sci Rep. 2019;9(1):17471.
  47. Grønningsæter IS, Fredly HK, Gjertsen BT, Hatfield KJ, Bruserud Ø. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. 2019;8(10). pii: E1229. doi: 10.3390/cells8101229.
  48. *Majumder MM, Leppä AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O’Gorman P, Wennerberg K, Porkka K, Gjertsen BT, Heckman CA. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types. Haematologica. 2019 Aug 22. pii: haematol.2019.217414. doi: 10.3324/haematol.2019.217414.
  49. Kreutzman A, Yadav B, Brummendorf TH, Gjertsen BT, Hee Lee M, Janssen J, Kasanen T, Koskenvesa P, Lotfi K, Markevärn B, Olsson-Strömberg U, Stentoft J, Stenke L, Söderlund S, Udby L, Richter J, Hjorth-Hansen H, Mustjoki S. Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line. Oncoimmunology. 2019 Jul 13;8(9):e1638210. doi: 10.1080/2162402X.2019.1638210.
  50. Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019 Oct;121(7):545-555.
  51. Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PØ, Rahman MA, Chekenya M. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers (Basel). 2019 Jul 17;11(7). pii: E996. doi: 10.3390/cancers11070996.
  52. Haugse R, Langer A, Gullaksen S-E, Sundøy SM, Gjertsen BT, Kotopoulis S, Emmet McCormack E. Intracellular signalling in key pathways is induced by treatment with ultrasound and microbubbles in a leukemia cell line, but not in healthy peripheral blood mononuclear cells. 2019; 11(7): 319
  53. Jebsen NL, Apelseth TO, Haugland HK, Rekdal Ø, Patel H, Gjertsen BT, Jøssang DE. Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report. J Med Case Rep. 2019 Jun 10;13(1):177. doi: 10.1186/s13256-019-2088-6.
  54. *Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. J Cancer Res Clin Oncol. 2019, May 20. doi: 10.1007/s00432-019-02931-1.
  55. Bischof K, Knappskog S, Hjelle SM, Stefansson I, Woie K, Salvesen HB, Gjertsen BT, Bjorge L. Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. Sci Rep. 2019; 9: 5244.
  56. Jørgensen KM, Mosleth EF, Liland KH, Nancy B. Hopf NB, Rita Holdhus R, Anne-Kristin Stavrum A-K, Gjertsen BT, Kirkeleit J. Global Gene Expression Response in Peripheral Blood Cells of Petroleum Workers Exposed to Sub-ppm Benzene Levels. Int J Envir Res Pub Health (IJERPH). 2018; 15(11). pii: E2385.
  57. Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomark Res. 2018 Nov 21;6:33.
  58. Reikvam H, Skavland J, Gullaksen SE, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT. Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case Rep Hematol.2018:2045985.
  59. Kirkeleit J, Riise T, Bjørge T, Christiani D, Bråtveit M, Baccarelli A, Mattioli S, Hollund BE, and Gjertsen BT. Maternal exposure to gasoline and exhaust increases the risk of childhood leukemia in offspring – a prospective study in the Norwegian Mother and Child Cohort Study. Br J Cancer. 2018;119(8):1028-1035.
  60. Gjerde C, Mustafa K, Hellem S, Rojewski M, Gjengedal H, Yassin MA, Feng X,Skaale S, Berge T, Rosen A, Shi XQ, Ahmed AB, Gjertsen BT, Schrezenmeier H, Layrolle P. Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial. Stem Cell Res Ther. 2018 Aug 9;9(1):213.
  61. Omsland M, Pise-Masison C, Fujikawa D, Galli V, Fenizia C, Parks RW, Gjertsen BT, Franchini G, Andresen V. Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine. Sci Rep. 2018 Jul 24;8(1):11118.
  62. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768-1777.
  63. *Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L. High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 2018 Jun 25;18(1):684.
  64. Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.
  65. Forthun RB, Aasebø E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.J Proteomics. 2018 Feb 20;173:32-41. doi: 10.1016/j.jprot.2017.11.014. Epub 2017 Nov 21. PMID: 29175091
  66. Laukkanen S, Grönroos T, Pölönen P, Kuusanmäki H, Mehtonen J, Cloos J, Ossenkoppele G, Gjertsen B, Øystein B, Heckman C, Heinäniemi M, Kontro M, Lohi O. In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL.  Blood Cancer J. 2017 Sep 8;7(9):e604. doi: 10.1038/bcj.2017.87. PMID: 28885610
  67. Reikvam H, Hovland R, Forthun RB, Erdal S, Gjertsen BT, Fredly H, Bruserud Ø. Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 2017 Sep 6;17(1):630. doi: 10.1186/s12885-017-3620-y. PMID: 28877686
  68. Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, Porkka K, Wolf D. NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.  2017 Oct;31(10):2264-2267. doi: 10.1038/leu.2017.235. Epub 2017 Jul 10. PMID: 28744011
  69. Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.  2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15. PMID: 28619982
  70. Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.  2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18. PMID: 28522574
  71. Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S. Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23. PMID: 28337541
  72. Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. J Clin Oncol. 2017 Jan 10;35(2):175-184. doi: 10.1200/JCO.2016.67.0893. Epub 2016 Nov 7. PMID: 28056193
  73. Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.  2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3. PMID: 28049642 Clinical Trial.
  74. Omsland M, Bruserud Ø, Gjertsen BT, Andresen V. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML). 2017 Jan 31;8(5):7946-7963. doi: 10.18632/oncotarget.13853. PMID: 27974700
  75. Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sørnes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016 Dec 1;7(12):e2497. doi: 10.1038/cddis.2016.392. PMID: 27906185
  76. Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvåle S, Sontum P, Gjertsen BT, Gilja OH, McCormack E. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. J Control Release. 2017 Jan 10;245:70-80. doi: 10.1016/j.jconrel.2016.11.019. Epub 2016 Nov 18. PMID: 27871988
  77. Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016 Dec 10;243:172-181. doi: 10.1016/j.jconrel.2016.10.007. Epub 2016 Oct 12. PMID: 27744037 Clinical Trial.
  78. Sulen A, Gullaksen SE, Bader L, McClymont DW, Skavland J, Gavasso S, Gjertsen BT. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacol Res. 2016 Nov;113(Pt A):216-227. doi: 10.1016/j.phrs.2016.08.018. Epub 2016 Aug 16. PMID: 27543462
  79. Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.  2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8. PMID: 27499136
  80. Sulen A, Lygre SH, Hjelle SM, Hollund BE, Gjertsen BT. Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion.  Sci Rep. 2016 Jul 6;6:29060. doi: 10.1038/srep29060. PMID: 27380711
  81. Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One. 2016 Jun 28;11(6):e0158208. doi: 10.1371/journal.pone.0158208. eCollection 2016. PMID: 27352023
  82. Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S, Olsson-Strömberg U. Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.  2016 Sep;30(9):1853-60. doi: 10.1038/leu.2016.121. Epub 2016 May 2. PMID: 27133821 Clinical Trial.
  83. Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S. Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy. Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22. PMID: 27006491
  84. Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.  2016 Feb 16;7(7):8105-18. doi: 10.18632/oncotarget.6991. PMID: 26812881
  85. Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015 Oct;2(10):e427-36. doi: 10.1016/S2352-3026(15)00148-9. Epub 2015 Sep 18. PMID: 26686044
  86. Sandtorv AH, Leitch C, Bedringaas SL, Gjertsen BT, Bjørsvik HR. 4-Alkylated Silver-N-Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells.  2015 Sep;10(9):1522-7. doi: 10.1002/cmdc.201500234. Epub 2015 Aug 6. PMID: 26250720
  87. Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells – high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.  2015 Feb 20;6(5):2794-811. doi: 10.18632/oncotarget.3056. PMID: 25605239
  88. Hampson P, Wang K, Ersvær E, McCormack E, Schüler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. 2014 Aug 6;1(8):529-39. doi: 10.18632/oncoscience.71. eCollection 2014. PMID: 25594060
  89. Mukherjee H, Chan KP, Andresen V, Hanley ML, Gjertsen BT, Myers AG. Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.  ACS Chem Biol. 2015 Mar 20;10(3):855-63. doi: 10.1021/cb500872g. Epub 2015 Jan 5. PMID: 25531824
  90. Landskron J, Helland Ø, Torgersen KM, Aandahl EM, Gjertsen BT, Bjørge L, Taskén K. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunol Immunother. 2015 Mar;64(3):337-47. doi: 10.1007/s00262-014-1636-6. Epub 2014 Nov 22. PMID: 25416072
  91. Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud Ø, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E, Bhatia R. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.  Cell Stem Cell. 2014 Oct 2;15(4):431-446. doi: 10.1016/j.stem.2014.08.001. PMID: 25280219
  92. Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006). Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13. PMID: 25082346
  93. Aasebø E, Vaudel M, Mjaavatten O, Gausdal G, Van der Burgh A, Gjertsen BT, Døskeland SO, Bruserud O, Berven FS, Selheim F. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.  2014 Sep;14(17-18):1971-6. doi: 10.1002/pmic.201300448. Epub 2014 Aug 8. PMID: 25044641
  94. Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116.
  95. Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud O, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014 May 21;13:116. doi: 10.1186/1476-4598-13-116.
  96. Helland O, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.  PLoS One. 2014 Mar 4;9(3):e89527. doi: 10.1371/journal.pone.0089527. eCollection 2014. PMID: 24594904
  97. Gavasso S, Mosleth EF, Marøy T, Jørgensen K, Nakkestad HL, Gjertsen BT, Myhr KM, Vedeler C. Deficient phosphorylation of Stat1 in leukocytes identifies neutralizing antibodies in multiple sclerosis patients treated with interferon-beta. PLoS One. 2014 Feb 19;9(2):e88632. doi: 10.1371/journal.pone.0088632. eCollection 2014. PMID: 2458636
  98. Kontro M, Kuusanmäki H, Eldfors S, Burmeister T, Andersson EI, Bruserud O, Brümmendorf TH, Edgren H, Gjertsen BT, Itälä-Remes M, Lagström S, Lohi O, Lundán T, Martí JM, Majumder MM, Parsons A, Pemovska T, Rajala H, Vettenranta K, Kallioniemi O, Mustjoki S, Porkka K, Heckman CA. Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia.  2014 Aug;28(8):1738-42. doi: 10.1038/leu.2014.89. Epub 2014 Feb 27. PMID: 24573384
  99. Rizzieri D, Vey N, Thomas X, Huguet-Rigal F, Schlenk RF, Krauter J, Kindler T, Gjertsen BT, Blau IW, Jacobsen TF, Johansen M, Bergeland T, Gianella-Borradori A, Krug U. A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course Leuk Lymphoma. 2014 Sep;55(9):2114-9. doi: 10.3109/10428194.2013.867489. Epub 2014 Jan 24. PMID: 24255981
  100.  Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, Almusa H, Bespalov MM, Ellonen P, Elonen E, Gjertsen BT, Karjalainen R, Kulesskiy E, Lagström S, Lehto A, Lepistö M, Lundán T, Majumder MM, Marti JM, Mattila P, Murumägi A, Mustjoki S, Palva A, Parsons A, Pirttinen T, Rämet ME, Suvela M, Turunen L, Västrik I, Wolf M, Knowles J, Aittokallio T, Heckman CA, Porkka K, Kallioniemi O, Wennerberg K. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013 Dec;3(12):1416-29. doi: 10.1158/2159-8290.CD-13-0350. Epub 2013 Sep 20. PMID: 24056683
  101. Fredly H, Ersvær E, Kittang AO, Tsykunova G, Gjertsen BT, Bruserud O. The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia. Clin Epigenetics. 2013 Aug 1;5(1):13. doi: 10.1186/1868-7083-5-13. PMID: 23915396
  102. Fredly H, Gjertsen BT, Bruserud O. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents.  Clin Epigenetics. 2013 Jul 30;5(1):12. doi: 10.1186/1868-7083-5-12. PMID: 23898968
  103. Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, Gilja OH, Postema M, Gjertsen BT,McCormack E. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.  Mol Imaging Biol. 2014 Feb;16(1):53-62. doi: 10.1007/s11307-013-0672-5. PMID: 23877869
  104. Bredholt T, Ersvær E, Erikstein BS, Sulen A, Reikvam H, Aarstad HJ, Johannessen AC, Vintermyr OK, Bruserud Ø, Gjertsen BT. Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine.  BMC Pharmacol Toxicol. 2013 Jul 11;14:35. doi: 10.1186/2050-6511-14-35. PMID: 23845085
  105. Herfindal L, Myhren L, Gjertsen BT, Døskeland SO, Gausdal G. Functional p53 is required for rapid restoration of daunorubicin-induced lesions of the spleen.  BMC Cancer. 2013 Jul 11;13:341. doi: 10.1186/1471-2407-13-341. PMID: 23841896
  106. Øye OK, Jørgensen KM, Hjelle SM, Sulen A, Ulvang DM, Gjertsen BT. Gel2DE – a software tool for correlation analysis of 2D gel electrophoresis data.  BMC Bioinformatics. 2013 Jul 6;14:215. doi: 10.1186/1471-2105-14-215. PMID: 23829206
  107. Andresen V, Wang X, Ghimire S, Omsland M, Gjertsen BT, Gerdes HH. Tunneling nanotube (TNT) formation is independent of p53 expression. Cell Death Differ. 2013 Aug;20(8):1124. doi: 10.1038/cdd.2013.61. Epub 2013 Jun 14 PMID: 23764777
  108. Reikvam H, Nepstad I, Sulen A, Gjertsen BT, Hatfield KJ, Bruserud Ø. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opin Investig Drugs. 2013 May;22(5):551-63. doi: 10.1517/13543784.2013.791280. PMID: 23586877
  109. Kloster MM, Naderi EH, Haaland I, Gjertsen BT, Blomhoff HK, Naderi S. cAMP signalling inhibits p53 acetylation and apoptosis via HDAC and SIRT deacetylases.  Int J Oncol. 2013 May;42(5):1815-21. doi: 10.3892/ijo.2013.1853. Epub 2013 Mar 8. PMID: 23483263
  110. Gausdal G, Wergeland A, Skavland J, Nguyen E, Pendino F, Rouhee N, McCormack E, Herfindal L, Kleppe R, Havemann U, Schwede F, Bruserud O, Gjertsen BT, Lanotte M, Ségal-Bendirdjian E, Døskeland SO. Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis. Cell Death Dis. 2013 Feb 28;4(2):e516. doi: 10.1038/cddis.2013.39. PMID: 23449452
  111. Silden E, Hjelle SM, Wergeland L, Sulen A, Andresen V, Bourdon JC, Micklem DR, McCormack E, Gjertsen BT. Expression of TP53 isoforms p53β or p53γ enhances chemosensitivity in TP53(null) cell lines.  PLoS One. 2013;8(2):e56276. doi: 10.1371/journal.pone.0056276. Epub 2013 Feb 11. PMID: 23409163
  112. Mustjoki S, Richter J, Barbany G, Ehrencrona H, Fioretos T, Gedde-Dahl T, Gjertsen BT, Hovland R, Hernesniemi S, Josefsen D, Koskenvesa P, Dybedal I, Markevärn B, Olofsson T, Olsson-Strömberg U, Rapakko K, Thunberg S, Stenke L, Simonsson B, Porkka K, Hjorth-Hansen H; Nordic CML Study Group (NCMLSG). Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.  2013 Jul;27(7):1520-6. doi: 10.1038/leu.2013.19. Epub 2013 Jan 18. PMID: 23328954
  113. McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, June CH, Kalos M, Ashfield R, Jakobsen BK. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.  Cancer Immunol Immunother. 2013 Apr;62(4):773-85. doi: 10.1007/s00262-012-1384-4. Epub 2012 Dec 22. PMID: 23263452
  114. Gjertsen BT, Wiig H. Investigation of therapy resistance mechanisms in myeloid leukemia by protein profiling of bone marrow extracellular fluid.  Expert Rev Proteomics. 2012 Dec;9(6):595-8. doi: 10.1586/epr.12.55. PMID: 23256670
  115. McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.  2013 Feb 14;121(7):e34-42. doi: 10.1182/blood-2012-05-429555. Epub 2012 Dec 12. PMID: 23243270
  116. McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens JB, Haug BE, Cooper ME, Gjertsen BT.Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013 Feb 15;73(4):1276-86. doi: 10.1158/0008-5472.CAN-12-2649. Epub 2012 Dec 10. PMID: 23233739
  117. Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H. Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid. PLoS One. 2012;7(11):e48992. doi: 10.1371/journal.pone.0048992. Epub 2012 Nov 14. PMID: 23155442
  118. Reikvam H, Kittang AO, Melve G, Mosevoll KA, Bentsen PT, Ersvær E, Gjertsen BT, Bruserud Ø. Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?  Curr Cancer Drug Targets. 2013 Jan;13(1):30-47. PMID: 22873213
  119. Hjelle SM, Sulen A, Øye OK, Jørgensen K, McCormack E, Hollund BE, Gjertsen BT. Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting. J Proteomics. 2012 Dec 5;76 Spec No.:69-78. doi: 10.1016/j.jprot.2012.07.021. Epub 2012 Jul 26. PMID: 22842154
  120. Tsykunova G, Reikvam H, Ahmed AB, Nepstad I, Gjertsen BT, Bruserud Ø. Targeting of polo-like kinases and their cross talk with Aurora kinases–possible therapeutic strategies in human acute myeloid leukemia? Expert Opin Investig Drugs. 2012 May;21(5):587-603. doi: 10.1517/13543784.2012.668525. Epub 2012 Mar 17. PMID: 22424119
  121. Oveland E, Wergeland L, Hovland R, Lorens JB, Gjertsen BT, Fladmark KE. Ectopic expression of Flt3 kinase inhibits proliferation and promotes cell death in different human cancer cell lines. Cell Biol Toxicol. 2012 Aug;28(4):201-12. doi: 10.1007/s10565-012-9216-z. Epub 2012 Mar 16. PMID: 22422053
  122. Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, Gjertsen BT, Madsen L, Marine JC, Blagoev B, Kristiansen K. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ. 2012 Aug;19(8):1381-9. doi: 10.1038/cdd.2012.15. Epub 2012 Mar 2. PMID: 22388350
  123. Hallenborg P, Feddersen S, Francoz S, Murano I, Sundekilde U, Petersen RK, Akimov V, Olson MV, Lozano G, Cinti S, Gjertsen BT, Madsen L, Marine JC, Blagoev B, Kristiansen K. Mdm2 controls CREB-dependent transactivation and initiation of adipocyte differentiation. Cell Death Differ. 2012 Aug;19(8):1381-9. doi: 10.1038/cdd.2012.15. Epub 2012 Mar 2. PMID: 22388350
  124. Fredly H, Reikvam H, Gjertsen BT, Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.  Am J Hematol. 2012 Apr;87(4):368-76. doi: 10.1002/ajh.23116. Epub 2012 Feb 28. PMID: 22374841 Clinical Trial.
  125. Gavasso S, Gjertsen B, Anderssen E, Myhr K, Vedeler C. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis. Mult Scler. 2012 Aug;18(8):1116-24. doi: 10.1177/1352458511434066. Epub 2012 Jan 27. PMID: 22287540
  126. Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status–consequences and potentials for pharmacological intervention. Br J Haematol. 2012 Feb;156(4):468-80. doi: 10.1111/j.1365-2141.2011.08960.x. Epub 2011 Dec 13. PMID: 22150087
  127. McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.  2012 May;26(5):910-7. doi: 10.1038/leu.2011.315. Epub 2011 Nov 8. PMID: 22064349
  128. Ånensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Hovland R, Taskén K, Knappskog S, Lønning PE, Bruserud Ø, Gjertsen BT. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. 2012 Mar 22;31(12):1533-45. doi: 10.1038/onc.2011.348. Epub 2011 Aug 22. PMID: 21860418

 

 

Invited reviews:

  1. Gjertsen BT. How to discover the exceptional venetoclax responders in AML/MDS? Br J Haematol. 2023 Nov 2. doi: 10.1111/bjh.19165. Epub ahead of print. PMID: 37920123.
  2. Hokland P, Fernández II, Freeman SD, Gjertsen BT, Jin J, Murthy V, Yanada M, Ganser A. AML in the elderly-A global view. Br J Haematol. 2023 Dec;203(5):760-773. doi: 10.1111/bjh.19135. Epub 2023 Oct 11. PMID: 37822071.
  3. Falini B, Gjertsen BT, Andresen V. The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML? 2023 Nov;37(11):2173-2175. doi: 10.1038/s41375-023-02037-1. Epub 2023 Sep 22. PMID: 37740103.
  4. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg T, Bjørge L, Blix E, Bjerkehagen B, Brabrand S, Cameron MG, Dalhaug A, Dietzel D, Dønnem T, Enerly E, Flobak Å, Fluge S, Gilje B, Gjertsen BT, Grønberg BH, Grønås K, Guren T, Hamre H, Haug Å, Heinrich D, Hjortland GO, Hovig E, Hovland R, Iversen AC, Janssen E, Kyte JA, von der Lippe Gythfeldt H, Lothe R, Lund JÅ, Meza-Zepeda L, Munthe-Kaas MC, Nguyen OTD, Niehusmann P, Nilsen H, Puco K, Ree AH, Riste TB, Semb K, Steinskog ESS, Stensvold A, Suhrke P, Tennøe Ø, Tjønnfjord GE, Vassbotn LJ, Aas E, Aasebø K, Tasken K, Smeland S. Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022 May 14;20(1):225. doi: 10.1186/s12967-022-03432-5. Erratum in: J Transl Med. 2022 Jul 15;20(1):317. PMID: 35568909; PMCID: PMC9107632.
  5. Taskén K, Russnes HEG, Aas E, Bjørge L, Blix ES; CONNECT Public–Private Partnership Consortium; Enerly E, Fagereng GL, Flobak Å, Gilje B, Gjertsen BT, Guren TK, Heix J, Hovig E, Hovland R; InPreD-Norway and National Molecular Tumor Board Consortium; IMPRESS-Norway Consortium; Lønning PE, Meza-Zepeda LA, Mæhle PM, Nilsen HL, Thoresen SØ, Widerberg K, Smeland S, Helland Å. A national precision cancer medicine implementation initiative for Norway. Nat Med. 2022 May;28(5):885-887. doi: 10.1038/s41591-022-01777-4. PMID: 35513529.
  6. Nordgård O, Brendsdal Forthun R, Lapin M, Grønberg BH, Kalland KH, Kopperud RK, Thomsen LCV, Tjensvoll K, Gilje B, Gjertsen BT, Hovland R. Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System. Cancers (Basel). 2021 Apr 13;13(8):1861.
  7. *Sletta K, Castells O, Gjertsen BT. Colony Stimulating Factor 1 receptor in Acute Myeloid Leukemia. Front. Oncol. 2021 doi: 10.3389/fonc.2021.654817.
  8. ***Gjertsen BT, Tislevoll BS, Fagerholt OHE, Hellesøy M. Early response evaluation in AML using mass cytometry. 2019 Jun 30;3(Suppl):3-5. doi: 10.1097/HS9.0000000000000215.
  9. *Andresen V, Gjertsen BT. Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy. Cancer J. 2019 Mar/Apr;25(2):153-163.
  10. Gavasso S, Gullaksen SE, Skavland J, Gjertsen BT. Single-cell proteomics: potential implications for cancer diagnostics. Expert Rev Mol Diagn. 2016;16(5):579-89. doi: 10.1586/14737159.2016.1156531. Epub 2016 Mar 21. PMID: 26895397 Review.
  11. Engen CB, Hajjar E, Gjertsen BT. Development of Personalized Molecular Therapy for Acute Myeloid Leukemia.Curr Pharm Biotechnol. 2016;17(1):20-9. doi: 10.2174/1389201016666150930115024.PMID: 26420051 Review.
  1. Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy.  2015 Jan;29(1):11-9. doi: 10.1038/leu.2014.222. Epub 2014 Jul 16. PMID: 25027517
  2. Engen CB, Wergeland L, Skavland J, Gjertsen BT. Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.  J Clin Med. 2014 Dec 15;3(4):1466-89. doi: 10.3390/jcm3041466. PMID: 26237612
  3. Gjertsen BT Jr. [Towards a more specific cancer treatment?].Tidsskr Nor Laegeforen. 2014 May 27;134(10):1017. doi: 10.4045/tidsskr.14.0574. eCollection 2014 May 27. PMID: 24865702 
  4. Bjugn R, Gjertsen BT. Human cells and the Norwegian Health Research Act Tidsskr Nor Laegeforen. 2012 Mar 6;132(5):540-2. doi: 10.4045/tidsskr.11.1076. PMID: 22398774 English, Norwegian.
  5. Giles F, Mahon FX, Gjertsen B, Swords R, Labar B, Turkina A, Rosti G. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia. Eur J Clin Invest. 2012 Sep;42(9):1016-26. doi: 10.1111/j.1365-2362.2012.02675.x. Epub 2012 May 1. PMID: 22548456 Review